For this reason and because immunotherapeutic agents as well as other therapeutic agents used in 31 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 this trial are known to be teratogenic, women of child- bearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for two months after study treatment . Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 2.1.1.9 Participants serologically positive for HIV, Hep B, Hep C are eligible as long as the viral loads are undetectable by quantitative PCR. HIV positive participants must have CD4 count ≥ 200 cells per cubic millimeter at enrollment, be on stable antiretroviral therapy for at least 4 weeks and have no reported opportunistic infections or Castleman’s disease within 12 months prior to enrollment. 2.1.1.10 Ability of subject to understand and the willingness to sign a written informed consent document. 2.1.2 Exclusion Criteria 2.1.2.1 Participants with prior investigational drug, chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 28 days prior to the first drug administration except if the investigator has assessed that all residual treatment -related toxicities have resolved or are minimal and feel the participant is otherwise suitable for enrollment. Participants may continue adjuvant hormonal therapy in the setting of a definitively treated cancer (e.g. , breast cancer ). 2.1.2.2 Known intolerance to or life threatening side effects resulting from prior checkpoint inhibitor therapy. 2.1.2.3 Major surgery within 28 days prior to the first drug administration (minimally invasive procedures such as diagnostic biopsies are permitted). 2.1.2.4 Known active brain or central nervous system metastasis (less than a month out from definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (<3 months) or clinically significant cerebrovascular accident (<3 months). In order to be eligible participants must have repeat CNS imaging at least a month after definitive treatment showing stable CNS disease. P articipants with evidence of intratumoral or peritumoral hemorrhage on baseline imaging are also excluded unless the hemorrhage is grade ≤ 1 and has been shown to be stable on two consecutive imaging scans. 2.1.2.5 Pregnant women are excluded from this study because these drugs have not been tested in pregnant women and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these immunotherapies, breastfeeding should be discontinued if the mother is treated on this protocol. 2.1.2.6 Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent with exception of: • Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease or other mild autoimmune disorders not requiring immunosuppressive treatment ; • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg of prednisone or equivalent per day; 32 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 • Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro -ocular, or inhalation) is acceptable; • Subjects on systemic intravenous or oral corticosteroid therapy with the exception of physiologic doses of corticosteroids (≤ the equivalent of prednisone 10 mg/day) or other immunosuppressives such as azathioprine or cyclosporin A are excluded on the basis of potential immune suppression. For these subjects these excluded treatments must be discontinued at least 1 weeks prior to enrollment for recent short course use (≤ 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (> 14 days). In addition, the use of corticosteroids as premedication for contrast -enhanced studies is allowed prior to enrollment and on study. 2.1.2.7 Subjects with a history of serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3 months) clinically significant bleeding events, or other illness considered by the Investigator as high risk for investigational drug treatment. 2.1.2.8 Subjects unwilling to accept blood products as medically indicated. 2.1.2.9 History of non- HPV associated second malignancy within 3 years of enrollment except localized malignancy which has been adequately treated or malignancy which does not require active systemic treatment (e.g ., low risk CCL). Patients taking adjuvant hormonal therapy for definitively treated cancers (e.g. breast cancer ) are eligible. 2.1.2.10 Subjects with a known severe hypersensitivity reaction to a monoclonal antibodies (grade >/= 3 NCI -CTCAE v5) will be evaluated by the allergy/immunology team prior to enrollment. 2.1.2.11 Receipt of prior lymphodepleting chemotherapy (e.g. cyclophosphamide, fludarabine) or any organ transplantation requiring ongoing immunosuppression. 2.1.3 Recruitment Strategies This study will be posted on www.clinicaltrials.gov , NIH websites and on NIH social media forums. After IRB approval of the recruitment material, this study may be advertised at national conferences including AACR and ASCO and may also be shared with the HPV and Anal Cancer Foundation who may advertise it further. Participants will be recruited from the current participant populat ion at NIH. Participants with HPV related cancers are currently being treated on another trial through LTIB, CCR, NIH, where 2-3 participants per month are being screening and enroll ed. Some of these participants come from established community networks, some of these participants are self -referrals , and some of these participants are referred by another group ( Dr. Hinrich s’s group, ETIB, CCR, NIH) who also have a large referral base for HPV related cancers. 2.2 SCREENING EVALUATION 2.2.1 Screening activities prior to the obtaining informed consent Minimal risk activities that may be performed before the subject has signed a consent include the following: • Email, written, in person or telephone communications with prospective subjects 33 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 • Review of existing medical records to include H&P, laboratory studies, etc. • Review of existing MRI, x-ray, or CT images • Review of existing photographs or videos • Review of existing pathology specimens/reports from a specimen obtained for diagnostic purposes 2.2.2 Screening activities performed after a consent for screening has been signed The following activities will be performed only after the subject has signed the study consent or the consent for study # 01C0129 (provided the procedure (s) are permitted on that study) on which screening activities will be performed . Assessments performed at outside facilities or on another NIH protocol within these timeframes below may also be used to determine eligibility once a participant has signed the consent. Within 28 days prior to enrollment , unless otherwise specified : • Complete medical history and physical examination (including height, weight, vital signs, and ECOG performance status). • CT of chest, abdomen and pelvis. • A brain CT scan in participants with known CNS disease as described in Section 2.1.2.4. • For skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion . • EKG • Clinical laboratory tests (within 16 days prior to enrollment). − Chemistry: sodium, potassium, chloride, bicarbonate, calcium, glucose, BUN, creatinine, ALT, AST, alkaline phosphatase, total protein, albumin, and total and direct bilirubin . − Hematology: complete blood count (CBC) with differential.